ArticleDocumenta ophthalmologica. Advances in ophthalmology2019
Fisetin rescues retinal functions by suppressing inflammatory response in a DBA/2J mouse model of glaucoma.
Article in Documenta ophthalmologica. Advances in ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 13 citations in OpenAlex.
- Nutritional Factors: Benefits in Glaucoma and Ophthalmologic Pathologies.Life (Basel, Switzerland) · 2023Review
- The Effects of Fisetin on Cyclosporine-Treated Dry Eye Disease in Dogs.International journal of molecular sciences · 2023Article
- Fisetin Prevents Angiogenesis in Diabetic Retinopathy by Downregulating VEGF.Journal of ophthalmology · 2023Article
- Glymphatic imaging and modulation of the optic nerve.Neural regeneration research · 2022Article
- Expression of Concern: Fisetin rescues retinal functions by suppressing inflammatory response in a DBA/2J mouse model of glaucoma.Documenta ophthalmologica. Advances in ophthalmology · 2019Article
- Inhibitory effect of Houttuynia cordata Thunb on LPS-induced retinal microglial activation.International journal of ophthalmology · 2019Article
- Immune Mediated Degeneration and Possible Protection in Glaucoma.Frontiers in neuroscience · 2019Review
Corrections and comments
- Expression of concern · 2019-11-15Concerns/Issues about Data · Concerns/Issues about Results and/or Conclusions · Concerns/Issues about Third Party Involvement ·
- Expression of concern
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGlaucoma is a common chronic neurodegenerative disease, which could lead to visual loss. In this study, we aimed to investigate whether fisetin, a natural flavone with anti-inflammatory and antioxidant properties, is able to alleviate glaucoma.
methodsWe employed a DBA/2J mouse model which was treated with or without fisetin. Pattern electroretinogram (P-ERG), visual evoked potentials (VEPs) and intraocular pressure (IOP) were evaluated. Quantitative real-time polymerase chain reaction and enzyme-linked immunosorbent assay (ELISA) were used to measure the expression levels of TNF-α, IL-1β and IL-6. Western blotting was performed to assess the activation of nuclear factor kappa-B (NF-κB).
resultsWe found that DBA/2J mice treated with fisetin (10-30 mg/kg) showed improved P-ERG and VEP amplitudes and reduced IOP compared to untreated DBA/2J mice. In addition, there were more survived retinal ganglion cells (RGCs) and less activated microglia in fisetin-treated DBA/2J mice than those in untreated mice. Furthermore, secreted protein levels and mRNA levels of TNF-α, IL-1β and IL-6 were significantly repressed by fisetin. The phosphorylated p65 level in the nucleus was dramatically reduced in fisetin-treated mice compared to it in untreated mice. Our results demonstrate that fisetin may exert its function through regulating cytokine productions and inhibiting NF-κB activation in the retina.
conclusionIn conclusion, fisetin is able to promote the visual functions of DBA/2J mice by inhibiting NF-κB activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.